New Advances in Melanoma

Melanoma is a very aggressive tumor which is derived from the transformation of pigment-producing cells termed the melanocytes. This cancer type accounts for most of the deaths associated with skin cancer as well as its incidence and is in constant evolution. Because of the rapid and very high metas...

Full description

Saved in:
Bibliographic Details
Sonstige:
Year of Publication:2022
Language:English
Physical Description:1 electronic resource (148 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
id 993545107804498
ctrlnum (CKB)5680000000037626
(oapen)https://directory.doabooks.org/handle/20.500.12854/81094
(EXLCZ)995680000000037626
collection bib_alma
record_format marc
spelling Larribère, Lionel edt
New Advances in Melanoma
Basel MDPI - Multidisciplinary Digital Publishing Institute 2022
1 electronic resource (148 p.)
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
Melanoma is a very aggressive tumor which is derived from the transformation of pigment-producing cells termed the melanocytes. This cancer type accounts for most of the deaths associated with skin cancer as well as its incidence and is in constant evolution. Because of the rapid and very high metastatic potential of this tumor, melanoma prognosis has been quite poor for a long time. In the past decade, groundbreaking discoveries in the melanoma research field have led to the development of two main treatment strategies: combination therapies targeting specific kinases or combination therapies focused on immune checkpoint inhibitors (ICIs). These treatment approaches have become the standard of care in most cancer centers and significantly improved the prognosis and overall survival of advanced melanoma patients. Nevertheless, many patients do not benefit from or even respond to these treatments. It is therefore essential to better comprehend the phenomenon of drug resistance, immune escape mechanisms, as well as to search for alternative treatment strategies. In addition, strong predictive biomarkers are desperately needed to improve clinical efficacy. The aim of this Special Issue is to present recent advances in the field of melanoma research, in which the abovementioned areas represent the primary focus, and other relevant themes are also discussed.
English
Public health & preventive medicine bicssc
melanoma
targeted therapies
BRAF
druggable mutations
real-time PCR
NGS assay
immune escape
microRNA
transporter associated with antigen processing
incidence
population-based study
epidemiology
Spain
skin cancer
single-cell transcriptome sequencing
treatment response
pseudotime analysis
treatment
ubiquitination
miRNAs
embryogenesis
melanoblasts
melanoblast
NF1
transcriptome
RNAseq
Trp-1
metastasis
animal models
lung
mice
3-0365-3453-9
3-0365-3454-7
Larribère, Lionel oth
language English
format eBook
author2 Larribère, Lionel
author_facet Larribère, Lionel
author2_variant l l ll
author2_role Sonstige
title New Advances in Melanoma
spellingShingle New Advances in Melanoma
title_full New Advances in Melanoma
title_fullStr New Advances in Melanoma
title_full_unstemmed New Advances in Melanoma
title_auth New Advances in Melanoma
title_new New Advances in Melanoma
title_sort new advances in melanoma
publisher MDPI - Multidisciplinary Digital Publishing Institute
publishDate 2022
physical 1 electronic resource (148 p.)
isbn 3-0365-3453-9
3-0365-3454-7
illustrated Not Illustrated
work_keys_str_mv AT larriberelionel newadvancesinmelanoma
status_str n
ids_txt_mv (CKB)5680000000037626
(oapen)https://directory.doabooks.org/handle/20.500.12854/81094
(EXLCZ)995680000000037626
carrierType_str_mv cr
is_hierarchy_title New Advances in Melanoma
author2_original_writing_str_mv noLinkedField
_version_ 1796652002257666048
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03187nam-a2200661z--4500</leader><controlfield tag="001">993545107804498</controlfield><controlfield tag="005">20231214133440.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202205s2022 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5680000000037626</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/81094</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995680000000037626</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Larribère, Lionel</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">New Advances in Melanoma</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (148 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Melanoma is a very aggressive tumor which is derived from the transformation of pigment-producing cells termed the melanocytes. This cancer type accounts for most of the deaths associated with skin cancer as well as its incidence and is in constant evolution. Because of the rapid and very high metastatic potential of this tumor, melanoma prognosis has been quite poor for a long time. In the past decade, groundbreaking discoveries in the melanoma research field have led to the development of two main treatment strategies: combination therapies targeting specific kinases or combination therapies focused on immune checkpoint inhibitors (ICIs). These treatment approaches have become the standard of care in most cancer centers and significantly improved the prognosis and overall survival of advanced melanoma patients. Nevertheless, many patients do not benefit from or even respond to these treatments. It is therefore essential to better comprehend the phenomenon of drug resistance, immune escape mechanisms, as well as to search for alternative treatment strategies. In addition, strong predictive biomarkers are desperately needed to improve clinical efficacy. The aim of this Special Issue is to present recent advances in the field of melanoma research, in which the abovementioned areas represent the primary focus, and other relevant themes are also discussed.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Public health &amp; preventive medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">melanoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">targeted therapies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">BRAF</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">druggable mutations</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">real-time PCR</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NGS assay</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune escape</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">microRNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">transporter associated with antigen processing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">incidence</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">population-based study</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">epidemiology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Spain</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">skin cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">single-cell transcriptome sequencing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">treatment response</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pseudotime analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">treatment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ubiquitination</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">miRNAs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">embryogenesis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">melanoblasts</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">melanoblast</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NF1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">transcriptome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">RNAseq</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Trp-1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metastasis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">animal models</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lung</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mice</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-3453-9</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-3454-7</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Larribère, Lionel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:54:21 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-05-14 21:41:54 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&amp;portfolio_pid=5337804900004498&amp;Force_direct=true</subfield><subfield code="Z">5337804900004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337804900004498</subfield></datafield></record></collection>